Arvinas, Inc. (ARVN) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for standing by. At this time, I would like to welcome everyone to our VINA's second quarter 2025 earnings call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. Thank you. I would now like to turn the conference over to Jeff Boyle, our VINA's Vice President of Investor Relations. Please go ahead. Good morning, everyone, and thank you for joining us. Earlier today, we issued a press release with our second quarter 2025 financial results, which is available in the investor and media section of our website at ourvinas.com. Joining the call today are John Hewson, our VINA's Chief Executive Officer, President, and Chairperson, Noah Berkowitz, our Chief Medical Officer, Angela Kakey, our Chief Scientific Officer, and Andrew Stake, our Chief Financial Officer. Before we begin the call, I'll remind you that today's discussion contains forward-looking statements that involve risks, uncertainties, and assumptions. These risks and uncertainties are outlined in today's press release and in the company's recent filing with the Securities and Exchange Commission, which I urge you to read. Our actual results are many different materially from what is discussed on today's call. And now I'll turn the call over to John. John? Thanks, Jeff. Good morning, everyone, and thank you for joining us today. As outlined in our second quarter earnings released this morning, our business is in a solid position with strong momentum. It was an eventful and exciting quarter at our VINA's with significant clinical and regulatory programs across our pipeline of pro-tag degrade...